Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report

Hdl Handle:
http://hdl.handle.net/10147/620781
Title:
Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report
Authors:
Cronin, Kevin C; Colleran, Gabrielle C; Smyth, Andrew; Houlihan, Diarmuid D; O'Gorman, Thomas A
Citation:
Cases Journal. 2009 Aug 25;2(1):6715
Issue Date:
25-Aug-2009
URI:
http://dx.doi.org/10.4076/1757-1626-2-6715; http://hdl.handle.net/10147/620781
Abstract:
Abstract A 32-year-old male presented with diarrhoea, mucus and bleeding per rectum. On the basis of sigmoidoscopy, rectal mesalazine was commenced uneventfully, and subsequently changed to oral mesalazine due to failure to improve. He re-presented 4 days later with frequent rigors, lethargy, palpitations and was generally unwell. His condition settled with conservative management and IV antibiotics. Oral mesalazine was withheld during the first 24 hours but was recommenced on day 2. After 2 doses he developed rigors, pyrexia, tachycardia and vomiting. Oral mesalazine was discontinued thereafter and his condition progressively improved. Mesalazine has not been re-introduced.
Language:
en
Keywords:
INFLAMMATORY BOWEL DISEASE

Full metadata record

DC FieldValue Language
dc.contributor.authorCronin, Kevin Cen
dc.contributor.authorColleran, Gabrielle Cen
dc.contributor.authorSmyth, Andrewen
dc.contributor.authorHoulihan, Diarmuid Den
dc.contributor.authorO'Gorman, Thomas Aen
dc.date.accessioned2016-09-30T11:20:07Z-
dc.date.available2016-09-30T11:20:07Z-
dc.date.issued2009-08-25-
dc.identifier.citationCases Journal. 2009 Aug 25;2(1):6715en
dc.identifier.urihttp://dx.doi.org/10.4076/1757-1626-2-6715-
dc.identifier.urihttp://hdl.handle.net/10147/620781-
dc.description.abstractAbstract A 32-year-old male presented with diarrhoea, mucus and bleeding per rectum. On the basis of sigmoidoscopy, rectal mesalazine was commenced uneventfully, and subsequently changed to oral mesalazine due to failure to improve. He re-presented 4 days later with frequent rigors, lethargy, palpitations and was generally unwell. His condition settled with conservative management and IV antibiotics. Oral mesalazine was withheld during the first 24 hours but was recommenced on day 2. After 2 doses he developed rigors, pyrexia, tachycardia and vomiting. Oral mesalazine was discontinued thereafter and his condition progressively improved. Mesalazine has not been re-introduced.en
dc.language.isoenen
dc.subjectINFLAMMATORY BOWEL DISEASEen
dc.titleHypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case reporten
dc.language.rfc3066enen
dc.rights.holderlicensee BioMed Central Ltd.en
dc.date.updated2016-04-15T16:04:06Zen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.